Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study

Recruiting now

Conditions studied: Childhood Acute Lymphoblastic Leukemia, Childhood Lymphoblastic Lymphoma

In brief

This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).

Key facts

Study ID

NCT07071051

Run by

Mayo Clinic

People needed

15

Starts

2025-07-31

Expected to finish

2026-12-31

Last updated by the study team

2026-02-13

Who can join

Age: 2 and older, up to 22. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 2-21.5 years
• Confirmed diagnosis of acute lymphoblastic leukemia/lymphoma
• Planned treatment with Cal-PEG
• Informed consent obtained from parents or guardians

You may not qualify if…

• Pre-existing coagulation disorders
• Known hypersensitivity to asparaginase products
• Liver failure
• Any acute or chronic disease that is known to affect coagulation testing (e.g. nephrotic syndrome)
• Currently pregnant
• Use of systemic blood thinner within 48 hours prior to study blood draw

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.